Mitsubishi UFJ Asset Management Co. Ltd. Increases Stock Holdings in CVS Health Corporation $CVS

Key Points

• Mitsubishi UFJ Asset Management increased its stake in CVS by 5.7% in Q4, buying 144,166 shares to hold 2,662,759 shares valued at about $213.37 million (≈0.21% ownership).
• CVS beat Q1 expectations with adjusted EPS $2.57 (vs. $2.21) and revenue $100.4B (vs. ~$95B) and raised FY2026 adjusted EPS guidance to $7.30–7.50, driven by improved Aetna medical cost controls and stronger pharmacy/benefits performance.
• CVS pays a $0.665 quarterly dividend (annualized $2.66, yield ~3.1%) though the payout ratio is high at 192.75%, and analysts maintain a consensus "Moderate Buy" with a $94.61 target price.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,662,759 shares of the pharmacy operator's stock after purchasing an additional 144,166 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.21% of CVS Health worth $213,367,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its stake in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after acquiring an additional 281 shares during the period. Ares Financial Consulting LLC acquired a new position in shares of CVS Health during the fourth quarter worth about $29,000. Corundum Trust Company INC purchased a new position in CVS Health during the third quarter worth about $29,000. GoalVest Advisory LLC purchased a new position in CVS Health during the fourth quarter worth about $32,000. Finally, Financial Consulate Inc. lifted its position in CVS Health by 99.6% in the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator's stock valued at $40,000 after purchasing an additional 249 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Price Performance

CVS stock opened at $86.89 on Thursday. The stock's 50 day moving average price is $76.60 and its 200 day moving average price is $78.00. The firm has a market cap of $111.35 billion, a P/E ratio of 62.96, a PEG ratio of 0.84 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $88.63.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts' consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts' expectations of $94.99 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 7.14 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date was Thursday, April 23rd. CVS Health's dividend payout ratio is 192.75%.

Wall Street Analyst Weigh In

CVS has been the topic of several recent analyst reports. Argus dropped their target price on CVS Health from $91.00 to $90.00 and set a "buy" rating on the stock in a research report on Wednesday, January 28th. Wolfe Research decreased their price target on CVS Health from $100.00 to $97.00 and set an "outperform" rating on the stock in a research note on Monday, March 2nd. The Goldman Sachs Group increased their price objective on CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. Sanford C. Bernstein raised CVS Health from a "market perform" rating to an "outperform" rating and raised their target price for the company from $91.00 to $94.00 in a report on Thursday, March 12th. Finally, Piper Sandler lowered their price target on shares of CVS Health from $101.00 to $99.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 31st. Twenty research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.61.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 beat and guidance raise — CVS reported adjusted EPS $2.57 vs. $2.21 expected, revenue $100.4B vs. ~$95B expected, and raised FY2026 adjusted EPS guidance to $7.30–7.50 (above street). Management cited improved medical cost controls at Aetna and stronger pharmacy/benefits performance, which explains the rally. PR Newswire: CVS first-quarter results
• Positive Sentiment: Improved insurance margins — Aetna reported a materially lower medical benefit ratio (~84.6% vs. 87.3% year-ago), helping margins and cash-flow outlook, a key driver of the upside in the stock. Reuters: CVS raises 2026 forecast
• Positive Sentiment: Cost control via formulary changes — CVS Caremark will prefer interchangeable biosimilars over some branded drugs (effective July 1), which should lower drug spend for clients and help pharmacy margins over time. PR Newswire: CVS Caremark biosimilar adoption
• Neutral Sentiment: Analyst and market context — HSBC nudged its price target slightly higher to $85 (hold), a modest validation but not a major catalyst. Macro beats (private payrolls) and calmer geopolitical headlines helped broader market sentiment. MarketScreener: HSBC raises PT Zacks: Private payrolls up
• Negative Sentiment: Formulary changes could trigger pushback — preferring biosimilars and dropping J&J’s Stelara from main formularies may prompt manufacturer, provider or political pushback and legal scrutiny, which could create noise or revenue disruption in specific categories. Reuters: CVS drops Stelara

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.